Lung cancer organoids in translational research: Bridging basic science, drug development, and clinical therapeutics

Lung cancer remains a leading cause of cancer-related deaths globally, presenting significant clinical challenges despite advancements in therapeutic strategies. Recent developments have highlighted the potential of lung cancer organoids as a promising tool to bridge basic science, drug development, and clinical therapeutics. This review focuses on the innovative role of lung cancer organoids in translational research, particularly their ability to integrate and accelerate the development of personalized treatment strategies. By mimicking patient-specific tumor microenvironments, lung cancer organoids provide an unparalleled platform for drug screening, evaluation of immune therapies, and assessment of anti-angiogenesis treatments. We posit that lung cancer organoids represent a cutting-edge, multidisciplinary tool with the potential to revolutionize cancer treatment and improve patient outcomes through enhanced translational research.